Free tool
FAERS Monitor: Proventil-Hfa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020503 or its brand name (Proventil-Hfa, Albuterol Sulfate). Reports on generic versions are filed under their own applications.
Reports
90,414
Serious
0
0% of reports
Hospitalization
18,506
Death reported
4,049
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea13,491
- wrong technique in product usage process10,981
- no adverse event8,673
- device delivery system issue8,098
- drug dose omission by device7,914
- asthma7,044
- cough6,601
- drug ineffective5,519
- fatigue5,275
- product dose omission issue5,123
- headache4,994
- off label use4,917
- wheezing4,406
- nausea4,173
- pneumonia4,027
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 280 |
| 2005 | 92 |
| 2006 | 73 |
| 2007 | 99 |
| 2008 | 345 |
| 2009 | 162 |
| 2010 | 191 |
| 2011 | 353 |
| 2012 | 496 |
| 2013 | 539 |
| 2014 | 665 |
| 2015 | 1,214 |
| 2016 | 2,108 |
| 2017 | 1,648 |
| 2018 | 1,882 |
| 2019 | 2,802 |
| 2020 | 6,163 |
| 2021 | 8,141 |
| 2022 | 9,724 |
| 2023 | 12,688 |
| 2024 | 14,923 |
| 2025 | 14,933 |
| 2026 | 10,893 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,963,745 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device delivery system issueSignal | 8,098 | 97.2 | 94.8 | 544,097 |
| drug dose omission by deviceSignal | 7,914 | 26.0 | 25.5 | 171,925 |
| wheezingSignal | 4,406 | 18.6 | 18.0 | 68,062 |
| asthmaSignal | 7,044 | 15.4 | 15.0 | 89,380 |
| wrong technique in product usage processSignal | 10,981 | 13.3 | 13.0 | 118,979 |
| no adverse eventSignal | 8,673 | 11.6 | 11.4 | 81,044 |
| dyspnoeaSignal | 13,491 | 5.7 | 5.6 | 51,853 |
| coughSignal | 6,601 | 5.6 | 5.5 | 24,576 |
| product dose omission issueSignal | 5,123 | 4.1 | 4.0 | 11,996 |
| pneumoniaSignal | 4,027 | 2.9 | 2.8 | 5,088 |
| headache | 4,994 | 1.9 | 1.8 | 2,029 |
| fatigue | 5,275 | 1.6 | 1.5 | 1,158 |
| off label use | 4,917 | 1.3 | 1.3 | 370 |
| nausea | 4,173 | 1.2 | 1.2 | 182 |
| drug ineffective | 5,519 | 1.0 | 0.9 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.